How Your Gut Talks to Your Brain — And Why GLP-1 Drugs Work Through This Connection

This is a narrative review published in the Journal of Clinical Investigation. The authors synthesized findings from human and animal studies across gastroenterology, neurology, psychiatry, and endocrinology to describe mechanisms of gut-brain communication and their clinical implications. No original experimental data was generated.

With millions of people now taking GLP-1 drugs like semaglutide and tirzepatide, understanding that these peptides work partly through gut-brain signaling pathways is crucial. This review provides the mechanistic framework explaining why GLP-1 drugs affect not just appetite and blood sugar, but also potentially mood, addiction, and neurological function — effects that have surprised both patients and clinicians.

This review arrives at a pivotal moment in peptide therapeutics. GLP-1 drugs are the fastest-growing drug class globally, and reports of unexpected effects on alcohol cravings, depression, and neuroinflammation have raised questions about how they really work. By mapping the gut-brain pathways these drugs engage, this review provides a scientific foundation for understanding their full spectrum of effects and for developing next-generation peptide therapies that deliberately target gut-brain communication.

As a review article, this synthesizes existing research rather than generating new data. The authors' interpretation of the literature reflects their perspective and may emphasize certain pathways over others. Many of the mechanistic pathways described are based on animal studies that may not fully translate to humans. The rapidly evolving nature of microbiome and GLP-1 research means some conclusions may be refined by newer findings.